Pfizer licenses Theravance's JAK inhibitors for skin conditions

Theravance与辉瑞公司签订全球许可协议

2019-12-24 13:36:36 seekingalpha

本文共389个字,阅读需1分钟

Theravance Biopharma  enters a global license pact with Pfizer for Theravance's preclinical program for skin-targeted, locally-acting pan-Janus kinase inhibitors that can be rapidly metabolized. Theravance will get up an upfront cash payment of $10M and will be eligible for up to an additional $240M in development and sales milestone payments from Pfizer. In addition, Theravance Biopharma will be eligible to receive royalties on worldwide net sales of any potential products emerging from the program. Pfizer gains 0.4% in premarket trading. "Topical JAK inhibitors that can be rapidly metabolized have potential to reach more patients with mild-to-moderate skin conditions, for whom treatment is currently limited," said Michael Vincent, chief scientific officer, Inflammation & Immunology, Pfizer. JAK inhibitors are currently approved for the treatment of a range of inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, myelofibrosis, and ulcerative colitis.
Theravrance Biopharma 公司与辉瑞(Pfizer)公司签订了一项全球许可协议,用于 Theravrance 公司针对皮肤靶向、局部作用的泛型 Janus 激酶抑制剂的临床前方案,该抑制剂可以快速代谢。 该公司将获得1000万美元的前期现金付款,并有资格从辉瑞(Pfizer)获得至多2.4亿美元的开发和销售里程碑付款。 此外, Theravance Biopharma 将有资格获得世界范围内任何潜在产品净销售额的特许权使用费。 辉瑞(Pfizer)在上市前交易中上涨0.4%。 “局部的 JAK 抑制剂,可以迅速代谢,有可能接触到更多的患者温和到中度皮肤条件,对他们的治疗目前是有限的,”迈克尔文森特说,首席科学官,炎症和免疫,辉瑞(Pfizer)。 JAK 抑制剂目前被批准用于治疗包括风湿性关节炎、银屑病关节炎、骨髓炎、溃疡性结肠炎等一系列炎症性疾病。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文